New Drug Application News and Research

RSS
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized cancer vaccines can be used to marshal powerful immune response

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

LEO Pharma A/S announces regulatory submission of  ENSTILAR® for psoriasis in Europe

LEO Pharma A/S announces regulatory submission of ENSTILAR® for psoriasis in Europe

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Mast plans to develop vepoloxamer for chronic heart failure treatment

Mast plans to develop vepoloxamer for chronic heart failure treatment

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Columbia Laboratories' revenues increase 11% to $32.5 million in 2014

Columbia Laboratories' revenues increase 11% to $32.5 million in 2014

Mylan releases Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr in U.S.

Mylan releases Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr in U.S.

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI acquires approved ANDA for Flecainide Acetate tablets USP

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014